Wang Jusi, Chen Zhan, Cao Rui, Zhang Qiang, Chen Tingyu, You Chengxiong, Tang Weifeng, Chen Shuchen
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Department of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212000, China.
Biomed Res Int. 2021 Jan 29;2021:9121824. doi: 10.1155/2021/9121824. eCollection 2021.
Studies have reported that and () polymorphisms may be associated with the risk to different cancers. However, the correlation between those variations and non-small-cell lung cancer (NSCLC) is still unclear. A total of 1,003 NSCLC patients and 901 noncancer controls were recruited in the study, to confirm the association of variations in gene with the risk of NSCLC. The SNPscan™ genotyping assay was used to obtain the genotypes of the four BTLA polymorphisms ( rs1982809 G>A, rs16859629 T>C, rs2171513 G>A, and rs3112270 A>G). It was found that rs1982809 polymorphism reduced the risk of NSCLC (GA vs. GG: adjusted odds ratio (OR) = 0.81, 95%confidence interval (CI) = 0.66-0.99, and = 0.043). However, the rs16859629, rs2171513, and rs3112270 polymorphisms showed no significant association between NSCLC patients and controls in overall comparison. In subgroup analyses, we found that rs1982809 polymorphism reduced the risk of NSCLC (nonsquamous cell carcinoma: GA vs. GG: adjusted OR = 0.79, 95%CI = 0.64-0.97, and = 0.026; AA/GA vs. GG: adjusted OR = 0.81, 95%CI = 0.66-0.99, and = 0.037; ≥59 years: GA vs. GG: = 0.036; never alcohol consumption: GA vs. GG: = 0.013; GA/AA vs. GG: = 0.016; body mass index (BMI) ≥ 24 kg/m: GA vs. GG: = 0.030; GA/AA vs. GG: = 0.041). The rs16859629 polymorphism increased the risk of the development of squamous cell carcinoma (CC vs. TT: adjusted OR = 9.85, 95%CI = 1.37-71.03, and = 0.023; CC vs. TT/TC: adjusted OR = 9.55, 95%CI = 1.32-68.66, and = 0.025). Taken together, the findings of the present suggest that rs1982809 and rs16859629 polymorphisms may influence the susceptibility to NSCLC in the Chinese population.
研究报告称,[基因名称1]和[基因名称2]([基因名称2]括号内英文为该基因简称)多态性可能与患不同癌症的风险相关。然而,这些变异与非小细胞肺癌(NSCLC)之间的相关性仍不清楚。本研究共招募了1003例NSCLC患者和901例非癌症对照,以确认[基因名称1]基因变异与NSCLC风险的关联。采用SNPscan™基因分型检测法获取四个BTLA多态性位点(rs1982809 G>A、rs16859629 T>C、rs2171513 G>A和rs3112270 A>G)的基因型。发现rs1982809多态性降低了NSCLC的风险(GA与GG相比:校正比值比(OR)=0.81,95%置信区间(CI)=0.66 - 0.99,P = 0.043)。然而,rs16859629、rs2171513和rs3112270多态性在总体比较中显示NSCLC患者与对照之间无显著关联。在亚组分析中,我们发现rs1982809多态性降低了NSCLC的风险(非鳞状细胞癌:GA与GG相比:校正OR = 0.79,95%CI = 0.64 - 0.97,P = 0.026;AA/GA与GG相比:校正OR = 0.81,95%CI = 0.66 - 0.99,P = 0.037;≥59岁:GA与GG相比:P = 0.036;从不饮酒:GA与GG相比:P = 0.013;GA/AA与GG相比:P = 0.016;体重指数(BMI)≥24 kg/m²:GA与GG相比:P = 0.030;GA/AA与GG相比:P = 0.041)。rs16859629多态性增加了鳞状细胞癌发生的风险(CC与TT相比:校正OR = 9.85,95%CI = 1.37 - 71.03,P = 0.023;CC与TT/TC相比:校正OR = 9.55,95%CI = 1.32 - 68.66,P = 0.025)。综上所述,本研究结果表明rs1982809和rs16859629多态性可能影响中国人群对NSCLC的易感性。